Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future

被引:20
作者
Yamashita, Hitomi [1 ]
Nakayama, Kentaro [1 ]
Ishikawa, Masako [1 ]
Ishibashi, Tomoka [1 ]
Nakamura, Kohei [1 ]
Sawada, Kiyoka [1 ]
Yoshimura, Yuki [1 ]
Tatsumi, Nagisa [1 ]
Kurose, Sonomi [1 ]
Minamoto, Toshiko [1 ]
Iida, Kouji [1 ]
Razia, Sultana [1 ]
Ishikawa, Noriyoshi [2 ]
Kyo, Satoru [1 ]
机构
[1] Shimane Univ, Dept Obstet & Gynecol, Sch Med, Izumo, Shimane 6938501, Japan
[2] Shimane Univ, Dept Organ Pathol, Sch Med, Izumo, Shimane 6938501, Japan
关键词
microsatellite instability; ovarian cancer; immune checkpoint inhibitor; immunohistochemistry; mismatch repair protein; REPAIR PROTEIN DEFECTS; REGULATORY T-CELLS; MAINTENANCE THERAPY; BREAST-CANCER; PD-1; BLOCKADE; TUMOR; MICROENVIRONMENT; CLASSIFICATION; OLAPARIB; PHASE-2;
D O I
10.3390/ijms20205129
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ovarian cancer has the worst prognosis among gynecological cancers. Thus, new ovarian cancer treatment strategies are needed. Currently, immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibody are attracting attention worldwide. The Food and Drug Administration approved the use of the PD-1 antibody pembrolizumab for solid cancers with microsatellite instability (MSI)-H or mismatch repair (MMR) deficiency in 2017. However, few studies on ovarian carcinoma have evaluated the relationship among MSI status, lymphocyte infiltration into the tumor, and the expression of immune checkpoint molecules by histologic type. We evaluated the expression of MMR proteins, tumor-infiltrating lymphocytes (CD8+), and immune checkpoint molecules (PD-L1/PD-1) by immunohistochemistry in 136 ovarian cancer patients (76, 13, 23, and 24 cases were high-grade serous, mucinous, endometrioid, and clear cell carcinoma, respectively) to investigate the effectiveness of immune checkpoint inhibitors. Only six cases (4.4%) had loss of MMR protein expression. There was no significant relationship between MSI status and age (p = 0.496), FIGO stage (p = 0.357), initial treatment (primary debulking surgery [PDS] or neoadjuvant chemotherapy) (p = 0.419), residual tumor after PDS or interval debulking surgery (p = 0.202), and expression of CD8 (p = 0.126), PD-L1 (p = 0.432), and PD-1 (p = 0.653). These results suggest that only a small number of MSI cases in ovarian cancer can be effectively treated with immune checkpoint inhibitor monotherapy. Therefore, to improve the prognosis of ovarian carcinoma, a combination therapy of immune checkpoint inhibitors and other anticancer drugs is necessary.
引用
收藏
页数:12
相关论文
共 46 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
    Allemani, Claudia
    Matsuda, Tomohiro
    Di Carlo, Veronica
    Harewood, Rhea
    Matz, Melissa
    Niksic, Maja
    Bonaventure, Audrey
    Valkov, Mikhail
    Johnson, Christopher J.
    Esteve, Jacques
    Ogunbiyi, Olufemi J.
    Azevedo e Silva, Gulnar
    Chen, Wan-Qing
    Eser, Sultan
    Engholm, Gerda
    Stiller, Charles A.
    Monnereau, Alain
    Woods, Ryan R.
    Visser, Otto
    Lim, Gek Hsiang
    Aitken, Joanne
    Weir, Hannah K.
    Coleman, Michel P.
    [J]. LANCET, 2018, 391 (10125) : 1023 - 1075
  • [3] Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability
    Aysal, Anil
    Karnezis, Anthony
    Medhi, Irum
    Grenert, James P.
    Zaloudek, Charles J.
    Rabban, Joseph T.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (02) : 163 - 172
  • [4] Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
    Bohm, Steffen
    Montfort, Anne
    Pearce, Oliver M. T.
    Topping, Joanne
    Chakravarty, Probir
    Everitt, Gemma L. A.
    Clear, Andrew
    McDermott, Jackie R.
    Ennis, Darren
    Dowe, Thomas
    Fitzpatrick, Amanda
    Brockbank, Elly C.
    Lawrence, Alexandra C.
    Jeyarajah, Arjun
    Faruqi, Asma Z.
    McNeish, Iain A.
    Singh, Naveena
    Lockley, Michelle
    Balkwill, Frances R.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (12) : 3025 - 3036
  • [5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [6] Mutation of the PIK3CA gene in ovarian and breast cancer
    Campbell, IG
    Russell, SE
    Choong, DYH
    Montgomery, KG
    Ciavarella, ML
    Hooi, CSF
    Cristiano, BE
    Pearson, RB
    Phillips, WA
    [J]. CANCER RESEARCH, 2004, 64 (21) : 7678 - 7681
  • [7] Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
    Chowell, Diego
    Morris, Luc G. T.
    Grigg, Claud M.
    Weber, Jeffrey K.
    Samstein, Robert M.
    Makarov, Vladimir
    Kuo, Fengshen
    Kendall, Sviatoslav M.
    Requena, David
    Riaz, Nadeem
    Greenbaum, Benjamin
    Carroll, James
    Garon, Edward
    Hyman, David M.
    Zehir, Ahmet
    Solit, David
    Berger, Michael
    Zhou, Ruhong
    Rizvi, Naiyer A.
    Chan, Timothy A.
    [J]. SCIENCE, 2018, 359 (6375) : 582 - +
  • [8] Screening for Ovarian Cancer
    Clarke-Pearson, Daniel L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) : 170 - 177
  • [9] Cancer immunoediting: from immunosurveillance to tumor escape
    Dunn, GP
    Bruce, AT
    Ikeda, H
    Old, LJ
    Schreiber, RD
    [J]. NATURE IMMUNOLOGY, 2002, 3 (11) : 991 - 998
  • [10] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    Gelmon, Karen A.
    Tischkowitz, Marc
    Mackay, Helen
    Swenerton, Kenneth
    Robidoux, Andre
    Tonkin, Katia
    Hirte, Hal
    Huntsman, David
    Clemons, Mark
    Gilks, Blake
    Yerushalmi, Rinat
    Macpherson, Euan
    Carmichael, James
    Oza, Amit
    [J]. LANCET ONCOLOGY, 2011, 12 (09) : 852 - 861